RE: RNS - Results for year end 202029 Apr 2021 08:20
the statement that stood out for me was...
"Large-scale deployment of the Parsortix system across numerous cancer types and application areas requires ANGLE to partner with large, global healthcare companies to take advantage of their distribution and sales channels and economic resources. Discussions continue with companies in relevant fields: medtech companies, pharma companies, contract research organisations and reference laboratories (laboratories offering clinical tests). We expect to see our partnership programme accelerate once FDA clearance for the Parsortix system has been achieved"
i think we'll be surprised how many pop up after approval. seems there are a few itching to partner up with AGL but need approval first.